Production of (S)-2-aminobutyric acid and (S)-2-aminobutanol in Saccharomyces cerevisiae
© The Author(s) 2017
Received: 10 December 2016
Accepted: 21 March 2017
Published: 23 March 2017
Saccharomyces cerevisiae (baker’s yeast) has great potential as a whole-cell biocatalyst for multistep synthesis of various organic molecules. To date, however, few examples exist in the literature of the successful biosynthetic production of chemical compounds, in yeast, that do not exist in nature. Considering that more than 30% of all drugs on the market are purely chemical compounds, often produced by harsh synthetic chemistry or with very low yields, novel and environmentally sound production routes are highly desirable. Here, we explore the biosynthetic production of enantiomeric precursors of the anti-tuberculosis and anti-epilepsy drugs ethambutol, brivaracetam, and levetiracetam. To this end, we have generated heterologous biosynthetic pathways leading to the production of (S)-2-aminobutyric acid (ABA) and (S)-2-aminobutanol in baker’s yeast.
We first designed a two-step heterologous pathway, starting with the endogenous amino acid l-threonine and leading to the production of enantiopure (S)-2-aminobutyric acid. The combination of Bacillus subtilis threonine deaminase and a mutated Escherichia coli glutamate dehydrogenase resulted in the intracellular accumulation of 0.40 mg/L of (S)-2-aminobutyric acid. The combination of a threonine deaminase from Solanum lycopersicum (tomato) with two copies of mutated glutamate dehydrogenase from E. coli resulted in the accumulation of comparable amounts of (S)-2-aminobutyric acid. Additional l-threonine feeding elevated (S)-2-aminobutyric acid production to more than 1.70 mg/L. Removing feedback inhibition of aspartate kinase HOM3, an enzyme involved in threonine biosynthesis in yeast, elevated (S)-2-aminobutyric acid biosynthesis to above 0.49 mg/L in cultures not receiving additional l-threonine. We ultimately extended the pathway from (S)-2-aminobutyric acid to (S)-2-aminobutanol by introducing two reductases and a phosphopantetheinyl transferase. The engineered strains produced up to 1.10 mg/L (S)-2-aminobutanol.
Our results demonstrate the biosynthesis of (S)-2-aminobutyric acid and (S)-2-aminobutanol in yeast. To our knowledge this is the first time that the purely synthetic compound (S)-2-aminobutanol has been produced in vivo. This work paves the way to greener and more sustainable production of chemical entities hitherto inaccessible to synthetic biology.
Keywords(S)-2-Aminobutyric acid l-Homoalanine (S)-2-Aminobutanol Carboxylic acid reductase l-Threonine 2-Ketobutyric acid Metabolic engineering Ethambutol
(S)-2-Aminobutyric acid (ABA), also known as l-homoalanine, is a non-proteinogenic α-amino acid, which is a chiral precursor for the enantiomeric pharmaceuticals levetiracetam, brivaracetam, and ethambutol [1, 2]. Enzymatic synthesis of chiral (R)- or (S)-2-aminobutyric acid has been reached by resolution of racemic mixtures with acylase [3, 4] or amidases , and asymmetric synthesis starting from 2-ketobutyric acid has been achieved using ω-transaminases [6, 7] or amino acid dehydrogenases . Both (R)- and (S)-2-aminobutyric acid were also synthesized using an (R)- or (S)-selective ω-transaminase and isopropylamine as co-substrate . Biosynthesis of (S)-2-aminobutyric acid (starting from the amino acid l-methionine) has been shown by co-immobilization of l-methionase and glutamate dehydrogenase on polyacrylamide or chitosan .
In contrast to in vitro synthesis with purified enzymes, whole-cell biocatalysts offer the advantage of simple and economical upstream processing as overheads for cell lysis, purification, and addition of co-factors are redundant. Low cost media and straightforward downstream processes further contribute to a more cost-effective production process. In vivo synthesis of (S)-2-ABA has been achieved via two different methods: (1) kinetic resolution of racemic 2-aminobutyric acid mixture with d-amino acid oxidase and ω-transaminase , and (2) asymmetric synthesis from l-threonine . The latter setup used five E. coli strains containing five different genes.
(S)-2-aminobutanol is an important chiral building block for the chemical synthesis of the bacteriostatic anti-tuberculosis agent (S, S)-ethambutol . Activity assays using Mycobacterium smegmatis have shown that the (S, S)-configured diastereomer of ethambutol [(S, S)-2,20-(ethylenediimino)-di-butanol] has the highest activity compared to all other measured derivatives, and is about 500 times more potent than the (R, R)-diastereomer . As ethambutol shows ocular toxicity as a side effect , it is desirable to keep the therapeutic dose as low as possible. Therefore, it is crucial to apply the potent (S, S)-configured diastereomer exclusively. Several approaches have been developed to achieve chemical synthesis of enantiopure (S, S) ethambutol; e.g. resolution of racemic (S)-2-aminobutanol [15, 16]; use of palladium to accomplish regio-and stereo-selective epoxide opening ; use of l-methionine as chiral starting material [18, 19]; and introduction of protection groups during synthesis [20, 21].
The application of engineered microorganisms for production of chemical building blocks with very high enantiomeric purity may help to improve the supply with cost-efficient active pharmaceutical compounds and, in contrast to chemical synthesis, no additional steps or protection groups are necessary. Increasingly, metabolic engineering and biotechnology are providing sustainable and cost-efficient production of precursors for a variety of pharmaceuticals [22–25].
To our knowledge, (S)-2-aminobutyric acid has not been produced in Saccharomyces cerevisiae, and (S)-2-aminobutanol has not yet been produced in any engineered microorganism. Here, we have explored the possibilities of using the well-known GRAS microorganism S. cerevisiae for biosynthesis of (S)-2-aminobutyric acid and subsequent production of (S)-2-aminobutanol. We demonstrate the in vivo production, in S. cerevisiae, of enantiopure (S)-2-aminobutyric acid and (S)-2-aminobutanol.
Production of (S)-2-aminobutyric acid
Yeast-endogenous enzymes CHA1 and/or ILV1 in principal can execute this first enzymatic step. Regulation of the corresponding encoding genes occurs in part at the promoter level: to overcome this regulation the coding sequences have been functionally linked to constitutive promoters. An alternative strategy using heterologous enzymes for this first step was also employed. We selected three heterologous threonine deaminases derived from Escherichia coli, Bacillus subtilis, and Solanum lycopersicum.
Based on the results from Zhang and co-workers we selected three mutated glutamate dehydrogenases (two from S. cerevisiae and one from E. coli) for the second enzymatic step . In addition, we assessed two different leucine dehydrogenases (from B. cereus and B. flexus), and a valine dehydrogenase (from S. fradiae) as putative enzymes for the amination step from 2-ketobutyric acid to (S)-2-aminobutyric acid [8, 27].
A less pronounced increase in (S)-2-ABA production was observed when using E. coli threonine deaminase (EcILVa) for the first enzymatic step (Fig. 2a, green bars). As the mutated E. coli GDH (EcGDH’) yielded the highest concentrations of (S)-2-ABA in combination with both ScCHA1 and EcILVa, we chose EcGDH’ to analyze the effect of the threonine deaminases derived from E. coli, B. subtilis, and S. lycopersicum on (S)-2-ABA production. Combining ILVa from B. subtilis with EcGDH’ led to the highest amount of (S)-2-ABA (0.40 ± 0.02 mg/L (S)-2-ABA, Fig. 2b). Expression of the heterologous enzymes had negligible effect on strain growth, as reflected by the relatively constant OD600 values after 24 h of culture.
Extension of the heterologous pathway for production of (S)-2-aminobutanol
We expressed one of four different carboxylic acid reductases (CARs) in combination with either a phosphopantetheinyl-transferase (PPTase) from M. smegmatis (for M. smegmatis CAR), or the one from B. subtilis (SFP) for all other CARs. CARs, when expressed in yeast, require a PPTase for activity . Expression of a heterologous aldehyde reductase derived from E. coli in our strains facilitated reduction of the (S)-2-aminobutanal to the corresponding alcohol (Fig. 3). Initial supplementation with additional (S)-2-ABA (0.5 g/L) was tested, as we observed rather low production of (S)-2-ABA.
Adjusting the culture medium to pH 7 boosted production levels. The neutral pH resulted in a significant increase of (S)-2-aminobutanol production in strains expressing M. marinum CAR (MmCAR). In those strains, we determined approximately 1.5-fold more (S)-2-aminobutanol under pH-adjusted growth conditions. Moreover, the strain expressing CAR from Nocardia iowensis (NiCAR) produced (S)-2-aminobutanol in quantifiable amounts when buffered to pH 7 (Fig. 4a, green bars). Integration of all pathway genes, including the CAR from M. marinum and its accessory protein SFP, resulted in an approximate threefold higher level of (S)-2-aminobutanol production compared with episomal expression of the pathway genes (Fig. 4b, green bars). Even without (S)-2-ABA supplementation, production levels of (S)-2-aminobutanol reached 0.45 ± 0.03 mg/L (Fig. 4b, red bars).
Increasing titers of (S)-2-aminobutyric acid
Optimizing enzymatic coupling
Increasing (S)-2-aminobutyric acid production by feeding l-threonine
l-Threonine is the starting molecule for enzymatic synthesis of (S)-2-aminobutyric acid. The concentration of l-threonine in our synthetic complete (SC) medium is 76 mg/L. When measured intracellularly upon 24 h of shake flask growth, the intracellular concentration of l-threonine is about 1.5–3 mg/L l-threonine (not shown). We hypothesized that elevating the l-threonine concentration may well influence (S)-2-ABA production.
Upregulation of l-threonine metabolism in S. cerevisiae by mutating HOM3 or deletion of GLY1
Mutation of aspartate kinase HOM3
Saccharomyces cerevisiae can synthesize l-threonine via a pathway that starts with the amino acid l-aspartate, and involves five enzymes (HOM3, HOM2, HOM6, THR1, and THR4) that assemble the amino acid via the four intermediates l-4-aspartyl-phosphate, l-aspartate-4-semialdehyde, l-homoserine, and O-phospho-l-homoserine . It is known that l-threonine inhibits aspartate kinase activity in S. cerevisiae  and several mutant strains that overproduce l-threonine have been isolated which all contained a mutation in the aspartate kinase gene HOM3 that led to insensitivity towards feedback inhibition [31, 32].
Deletion of threonine aldolase (GLY1)
In this study, we describe: (1) the production of enantiopure (S)-2-aminobutyric acid in Saccharomyces cerevisiae by expressing two heterologous genes that convert l-threonine to (S)-2-aminobutyric acid; (2) the prolongation of the pathway from (S)-2-aminobutyric acid to (S)-2-aminobutanol by expressing three additional heterologous genes. Both compounds are of considerable interest due to their potential use for the production of the chiral anti-epileptic drugs levetiracetam and brivaracetam, as well as for the production of the chiral anti-tuberculosis drug ethambutol. The latter one figures on the WHO list of essential medicines.
Pathway to (S)-2-aminobutyric acid
We show that expression of B. subtilis threonine deaminase, combined with expression of a mutated form of E. coli glutamate dehydrogenase leads to the production of 0.40 ± 0.02 mg/L of (S)-2-aminobutyric acid in shake flask-grown S. cerevisiae cells. The higher production in E. coli achieved by Zhang and co-workers  is perhaps due to the special properties of the E. coli strain employed, which can produce 8 g/L l-threonine from 30 g/L glucose. Nevertheless, we rationalize that yeast is indeed a superior production host for (S)-2-aminobutanol production, as it displays higher robustness and considerable tolerance against harsh fermentation conditions. Yeast is also more resistant towards exposure to (S)-2-aminobutanol (Additional file 1: Figure S4). Moreover, the fermentation of yeasts is easily implemented into existing ethanol productions plants, and there are no issues with phage contamination. S. cerevisiae is classified as GRAS (“generally regarded as safe”) organism; thereby further facilitating industrial scale up.
We have explored a variety of strategies to increase the yield of (S)-2-ABA production in our yeast strains; first by evaluating the effect of adding a second copy of mutated glutamate dehydrogenase. When analyzing intracellular 2-ketobutyric acid concentrations we realized that in yeasts containing the enzyme combinations threonine deaminase from S. lycopersicum and mutated glutamate dehydrogenase from E. coli, a considerable amount of 2-ketobutyric acid (0.98 ± 0.03 mg/L) was not converted to (S)-2-aminobutyric acid. This may be due to the relatively low Km value of this heterologous l-threonine deaminase (SlTD: 0.25 mM, ). In contrast, the deaminase from E. coli has a Km of 11 mM (if AMP is present, otherwise it is 91 mM) , and the one from B. subtilis is 9.6 mM . The amount of l-threonine generated in the strains after 24 h of growth in shake flasks reaches approximately 2 mg/L (~0.017 mM intracellular l-threonine). This low intracellular l-threonine concentration can be more efficiently converted to 2-ketobutyric acid by SlTD as this deaminase has a lower Km than the other threonine deaminases.
It is expected that the obvious massive increase in production of 2-ketobutyric acid by SlTD would lead to a substantial elevation of (S)-2-ABA accumulation, especially taking into account the relatively high Km (8.4 mM) of EcGDH’ . As this was not the case, the enzymatic capacity of E. coli glutamate dehydrogenase was enhanced by expressing a second copy of this enzyme in the yeast. The modification elevated the amount of (S)-2-aminobutyric acid, but a considerable amount of 2-ketobutyric acid remained. This indicates that production of (S)-2-ABA may not be massively tunable, probably due to substrate inhibition of the E. coli dehydrogenase . This hypothesis is further substantiated by the fact that in threonine fed strains expressing SlTD and EcGDH’, 2-ketobutyric acid production was elevated to above 4.54 ± 0.93 mg/L, without increasing intracellular (S)-2-aminobutyric acid accumulation.
Feeding with l-threonine elevated intracellular (S)-2-ABA accumulation in strains expressing the enzyme combination BsILVa and EcGDH’ more than fourfold compared to non-fed strains.
The conversion yield of l-threonine to (S)-2-ABA (no additional l-threonine) was 36% compared to 22% with additional l-threonine in the medium, indicating that l-threonine is consumed by enzymatic and/or efflux reactions triggered by the elevated intracellular l-threonine concentration.
Interestingly, in contrast to the non-fed strains, most of the de novo (S)-2-ABA was found in the supernatant, indicating that (S)-2-ABA was either actively secreted, or passively diffused. l-Threonine strongly induces the broad-specificity amino acid permease AGP1 [40, 41], suggesting that this permease may not only mediate uptake of l-threonine, but also increase (S)-2-ABA efflux. Another putative mediator of (S)-2-ABA efflux could be the internal-membrane transporter AQR1. This transporter is involved in excretion of excess amino acids by exocytosis , suggesting that it may also secrete (S)-2-ABA.
As feeding with l-threonine significantly boosted (S)-2-ABA production, we hypothesized that upregulation of threonine anabolism may enhance generation of (S)-2-ABA in our engineered strains.
The G425D mutation of aspartate kinase HOM3, previously described to abrogate feedback-inhibition, led to a significant boost of both intracellular l-threonine and (S)-2-aminobutyric acid. Recently, Mülleder et al. analyzed the amino acid metabolome of S. cerevisiae upon systematic gene deletions . They found that deletion of FPR1 (a peptidyl-prolyl cis–trans isomerase) enhanced intracellular l-threonine by around 2.5-fold. This increase is in good accordance with our HOM3 mutant, indicating that FPR1 may indeed regulate feedback inhibition of HOM3 as previously suggested [31, 44]. l-Threonine and (S)-2-aminobutyric acid were also detected at higher extracellular levels upon expression of the mutated form of HOM3. Those data indicate that the endogenous l-threonine supply is indeed critical for (S)-2-ABA production.
The l-threonine aldolase GLY1 of S. cerevisiae catalyzes the cleavage of l-threonine into l-glycine and acetaldehyde. In contrast to expectations, no elevated l-threonine levels were detected in Δgly1 deletion strains. The comparable concentrations of l-threonine accumulated in wild type and Δgly1 deletion strains led us to conclude that feedback inhibitory mechanisms are active e.g. aspartate kinase HOM3. Our Δgly1 deletion strains showed strongly impaired growth characteristics compared to the wildtype strains (four to fivefold lower). These growth characteristics are similar to the ones previously reported , suggesting that GLY1 is important for l-glycine synthesis.
Pathway to (S)-2-aminobutanol
Here, we report production of the non-natural compound (S)-2-aminobutanol in S. cerevisiae. The highest production levels were observed in strains expressing (apart from the enzymes forming the (S)-2-aminobutyric acid pathway) M. marinum carboxylic acid reductase and an aldehyde reductase from E. coli. The level of 0.42 ± 0.07 mg/L (S)-2-aminobutanol could be reached by buffering the growth medium to pH 7. Valli and co-workers  demonstrated previously that yeast cells grown at pH 7 are viable and adjust their endogenous pH accordingly. Furthermore, CARs work predominantly at basic pH conditions . We hypothesized therefore that adjusting the culture medium to pH 7 would increase intracellular pH and lead to elevated activity of heterologous CARs. Our results support this hypothesis. Without pH adjustment of the surrounding medium, the extracellular pH drops to pH 2.5 in stationary phase  that would correspond to an intracellular pH around 5, which is not suitable for CAR activity .
Interestingly, integration of the entire pathway into a single position of chromosome XI significantly enhanced production of (S)-2-aminobutanol, even though promoters and terminators of the heterologous genes were identical to those used for episomal expression. Growth of strains expressing the plasmid-encoded pathway was however significantly lower than yeast strains expressing the genome-integrated pathway. These results indicate that plasmid maintenance is perhaps at the expense of heterologous pathway expression and product generation. However, strains expressing the pathway also displayed retarded growth. One explanation for impaired cellular growth and proliferation are the reductive modifications of intracellular fatty acids or reduction of fatty acids that form parts of membrane lipids by CARs [46, 47]. Ultimately, compartmentalization of the heterologous pathway might be a valuable approach for efficient orthologous production of this non-natural chiral compound.
Previous studies have demonstrated that substrates with an amine group at the α-position are scarcely accepted by carboxylic acid reductases , suggesting that production of (S)-2-aminobutanol may be further boosted by optimizing the substrate binding site of the carboxylic acid reductase.
Co-factor supply in the pathway
Threonine deaminases are pyridoxal-5′-phosphate (PLP) dependent, with the PLP co-factor remaining in the active site and being regenerated during the reaction cycle . In S. cerevisiae PLP levels are elevated when the yeasts are grown under thiamine deficient conditions as the synthesis of PLP is inhibited by the presence of thiamine . Enhanced conversion in whole-cell biocatalysis experiments employing PLP-dependent ω-transaminases and addition of PLP or preceding growth in thiamine-deficient medium have been shown [50, 51].
Most of the enzymes in the pathway to (S)-2-aminobutanol require NADPH. Elevated NADPH supply should boost production of (S)-2-aminobutyric acid and (S)-2-aminobutanol, as shown previously for several other cofactor-dependent enzymatic reactions [52–55]. NADPH is generated predominantly by the pentose phosphate pathway. A recent study has shown that overexpression of glucose-6-phosphate dehydrogenase ZWF1, the enzyme that catalyzes the first step of the pentose phosphate pathway, or overexpression of NADH kinase POS5 leads to a higher of NADPH-dependent heterologous production of β-carotene in S. cerevisiae . In future studies, we will use the described approaches to enhance the efficiency of the heterologous pathway.
We have successfully assembled a heterologous metabolic pathway in S. cerevisiae to produce the non-proteinogenic amino acid (S)-2-aminobutyric acid and the purely synthetic compound (S)-2-aminobutanol. To our knowledge (S)-2-aminobutanol has never previously been produced biosynthetically. Our studies expand the spectrum of synthetic biology towards the biosynthesis of e.g. pharmaceutical compounds by entirely novel and sustainable means.
Chemicals and media
l-threonine, 2-ketobutyric acid, (R)- and (S)-aminobutyric acid, (R) and (S)-2-aminobutanol were bought from Sigma-Aldrich Chemie AG (Steinheim, Germany). Yeast Extract Peptone (YPD) medium with 20 g/L glucose was used for growth of the wildtype strain prior to transformation and both bought from Sigma-Aldrich Chemie AG. Synthetic complete (SC) drop out medium (Formedium LTD, Hustanton, England) with 6.7 g/L yeast nitrogen base without amino acids and ammonium sulfate (Sigma-Aldrich Chemie AG), and 20 g/L glucose (Sigma-Aldrich Chemie AG) was used for pre- and main cultures. LB medium for growth of E. coli was supplied from Carl Roth GmbH + Co. KG (Karlsruhe, Germany).
Primers, genes, and strains
Expression cassettes and plasmids
Glutamate dehydrogenase (K74V/T177S)
Glutamate dehydrogenase (K75V/T178S)
Glutamate dehydrogenase (K92V/T195S)
Carboxylic acid reductase
Carboxylic acid reductase
Carboxylic acid reductase
Carboxylic acid reductase
Origin of replication
Aspartate kinase (G425D)
Glutamate dehydrogenase (K92 V/T195S)
Replication origin/integration site
Contains expression cassettes of ScCHA1 and ScGDH1′
Contains expression cassettes of ScCHA1 and ScGDH3′
Contains expression cassettes of ScCHA1 and EcGDH’
Contains expression cassettes of ScCHA1 and BcLeuDH
Contains expression cassettes of ScCHA1 and BfLeuDH
Contains expression cassettes of ScGDH1′ and EcILVa
Contains expression cassettes of ScGDH3′ and EcILVa
Contains expression cassettes of EcGDH’ and EcILVa
Contains expression cassettes of EcILVa and BcLeuDH
Contains expression cassettes of EcILVa and BfLeuDH
Contains expression cassettes of ScCHA1 and SfValDH
Contains expression cassettes of EcILVa and SfValDH
Contains expression cassettes of ScCHA1, EcGDH’, NiCAR, EcALR, and BsSFP
Contains expression cassettes of ScCHA1, EcGDH’, NfCAR, EcALR, and BsSFP
Control strain with empty entry vectors
Contains expression cassettes of BsILVa and EcGDH’
Contains expression cassettes of ScILV1 and EcGDH’
Contains expression cassettes of SlTD and EcGDH’
Contains expression cassette of ScHOM3-R2
Contains expression cassettes of BsILVa, EcGDH’, and ScHOM3-R2
URA3 (BsILVa, EcGDH’), LEU2 (ScHOM3-R2)
ARS/CEN (BsILVa, EcGDH’)
2 micron (ScHOM3-R2)
Contains expression cassettes of EcILVa, EcGDH’, MsCAR, MsPPTase, and EcALR
Contains expression cassette of SlTD and two EcGDH’ expression cassettes
Deletion of GLY1 ORF
Deletion of GLY1 ORF
Contains expression cassettes of BsILVa and EcGDH’
Deletion of GLY1 ORF
Contains expression cassettes of SlTD and EcGDH’
Contains expression cassettes of BsILVa, EcGDH’, MmCAR, EcALR, and BsSFP
Control strain with empty plasmid
Contains expression cassettes of BsILVa, EcGDH’, and empty plasmid
URA3 (BsILVa, EcGDH’), LEU2
ARS/CEN (BsILVa, EcGDH’)
2 micron (empty plasmid)
Contains expression cassettes of SlTD, EcGDH’, and empty plasmid
URA3 (BsILVa, EcGDH’), HIS3
Contains expression cassettes of BsILVa, EcGDH’, MmCAR, EcALR, and BsSFP
integrated into Chromosome XI-2
Plasmid DNA was prepared using the ZR Plasmid Miniprep-Classic Kit (Zymo Research Corp, Irvine, CA, USA). Competent E. coli NEB 10-β cells (New England Biolabs, Herts, United Kingdom) were used for all cloning steps. Restriction enzymes were supplied from New England Biolabs (Herts, United Kingdom). T4 ligase was from Agilent (Santa Clara, CA, USA), and thermostable DNA polymerase iProof™ High-Fidelity was purchased from BioRad (Hercules, CA, USA). dNTPs were from Roche Diagnostics GmbH (Mannheim, Germany). PCR reactions were performed in a FlexCycler2 (Analytik Jena AG, Jena, Germany) using the appropriate cycling conditions. PCR products were purified using the DNA Clean & Concentrator-5 Kit from Zymo Research Corp (Irvine, CA, USA). Accuracy of genetic constructs was verified by sequencing (Microsynth AG, Balgach, Switzerland).
Plasmid construction, gene deletion, and integration
Most of the genes used in this study were supplied in plasmids as yeast-codon optimized versions of the original genes (GeneArt, Thermo Fisher Scientific, Waltham, MA, USA). Genes were released from the plasmids, supplied by the manufacturer, by HindIII/SacII digestions prior to ligation into our pre-cut entry vectors. Our entry vectors contain different combinations of promoters and terminators, which are flanked by 60 bp homologous regions (“linkers”) that enable the assembly of multiple expression cassettes in vivo by homologous recombination [57, 58]. Accessory entry vectors dispose of autonomously replicating sequences, centromere regions, and auxotrophic markers as described in Eichenberger et al. . One-pot digestion of entry vectors by AscI releases the expression cassettes composed of (1) promoter-gene-terminator flanked by 60 bp linkers at the 5′ and 3′ end; (2) selection marker URA3 flanked by 60 bp linkers at the 5′ and 3′ end; and (3) replication origin ARS/CEN flanked by 60 bp linkers at the 5′ and 3′ end); or, for integration, two 560 bp homologous regions flanked by 60 bp linkers at the 5′ and 3′ sites. Released fragments were then transformed into the strains as described in the next paragraph.
Amplification of the plasmids containing the carboxylic acid reductase from Nocardia farcinica has been reported to be not feasible in E. coli (personal communication Esben H. Hansen). Therefore, the gene was ordered in two fragments, containing a 60 bp homologous region. The entire open reading frame was fused in vivo in yeast. Correct assembly was confirmed by PCR amplification and subsequent sequencing.
HOM3 was amplified from yeast genomic DNA in three parts. The three sequence stretches were fused by overlap extension PCR thereby removing the HindIII site and mutating glycine 425 to aspartic acid. The resulting entire PCR product was cut with HindIII and SacII, and inserted into a 2μ yeast expression plasmid.
The ORF encoding GLY1 was deleted by transformation of a PCR product encoding the marker LEU2 flanked by homologous regions upstream and downstream of the genomic GLY1 ORF. Successful deletion was confirmed by colony PCR.
The five pathway genes (BsILVa, EcGDH’, MmCAR, BsSFP, EcALR) were integrated by homologous recombination of the same cassettes as used for the episomal expression plasmid (described before), except that the centromere region was exchanged with the homologous region on chromosome XI-2 (noncoding region between FAT3 and MTR2).
Transformation and cell growth
Yeast transformation was performed using the lithium acetate method described in . Transformed clones were grown on agar plates prepared with selective SC drop out medium. Single colonies from the plates were inoculated into 3 mL of selective liquid SC medium and grown overnight at 30 °C in a shaker (160 rpm). Main cultures (25 mL in 250 mL shake flasks) for production of (S)-2-ABA were inoculated at a starting OD600 of 0.1, and kept on the shaker at 30 °C for 24–72 h. The main cultures for (S)-2-aminobutanol were carried out in 24 deepwell plates (OD 0.1, 2.5 mL, 72 h, 30 °C, 300 rpm; Porvair, Norfolk, UK).
Cell suspensions in 10 mL of growth medium were harvested by centrifugation at 4000 rpm for 5 min. One millilitre of the supernatant was removed for analysis. The remaining cell pellet was resuspended in 1 mL water and added to a 2 mL screw cap tube containing 500 µL glass beads (0.5 mm, Huberlab, Aesch, Switzerland). Cell lysis was performed by a precellys 24 bead beater (Bertin technologies, Aix-en-Provence Cedex, France) for 3 cycles for 45 s with 60 s break. Cell debris was removed by centrifugation (14,000 rpm, 5 min), and the supernatant was subjected to analyses.
Stock solutions of (R)- and (S)-2-aminobutyric acid, l-threonine, 2-ketobutyric acid, and 2-aminobutanol (1 g/L) were prepared in water. Calibration standards of those compounds were prepared in the range of 31 μg/L–8 mg/L in water/acetonitrile 85:15.
Pellet extracts (150 μL) or supernatants (150 μL) were diluted into 850 μL of acetonitrile (in order to precipitate protein remainings), and centrifuged prior to injection.
Threonine, 2-ketobutyric acid, 2-aminobutyric acid, and 2-aminobutanol analysis
Samples were injected into an Acquity UPLC-TQD (Waters), equipped with an Aquity UPLC BEH Amide 1.7 μm 2.1 × 100 mm (Waters) column with two mobile phases. A: water with 10 mM ammonium formate and 0.15% formic acid, and B: acetonitrile with 2 mM ammonium formate and 0.05% formic acid. Separation was performed with a gradient ranging from 85 to 82% of mobile phase B for 3 min then to 60% B in 1 min at a flow rate of 0.6 mL/min. Then a washing step at 60% B for 1 min, followed by a reconditioning step of 1 min at 85% B, was carried out. 2-Ketobutyric acid was detected with SIR mode following the mass 101.1 in ESI- with a cone voltage of 20 V. 2-Aminobutanol, 2-aminobutyric acid, and l-threonine were detected with MRM mode with the transitions 90.1 > 55, 104.1 > 58, 120 > 74 in ESI+ , cone voltages of 18, 16 and 16 V and collision voltages of 12 V for all compounds.
2-Aminobutyric acid chiral analysis
Samples were injected on an Aquity UPLC-TQD (Waters) equipped with an Astec Chirobiotic T 250 × 4.6 mm column (Sigma) with water/methanol/formic acid 30:70:0.02 isocratic mobile phase and 1 mL/min flow during 16 min. (R)- and (S)-aminobutyric acid were detected with MRM mode with the transition 104.1 > 58.0 in ESI+ , a cone voltage of 16 V and collision voltage of 12 V (Additional file 1: Figure S1).
(S)-2-aminobutyric acid (synonyms: α-aminobutyric acid, l-homoalanine)
Saccharomyces cerevisiae threonine deaminase CHA1
Escherichia coli threonine deaminase ILVa
Bacillus subtilis threonine deaminase ILVa
Saccharomyces cerevisiae threonine deaminase ILVa
Solanum lycopersicum threonine deaminase
Saccharomyces cerevisiae glutamate dehydrogenase 1 (K74V/T177S)
Saccharomyces cerevisiae glutamate dehydrogenase 3 (K75V/T178S)
Escherichia coli glutamate dehydrogenase (K92V/T195S)
Bacillus cereus leucine dehydrogenase
Bacillus flexus leucine dehydrogenase
Streptomyces fradiae valine dehydrogenase
Nocardia iowensis carboxylic acid reductase
Nocardia farcinica carboxylic acid reductase
Mycobacterium smegmatis carboxylic acid reductase
Mycobacterium marinum carboxylic acid reductase
Saccharomyces cerevisiae aspartate kinase (G425D)
Escherichia coli aldehyde reductase
Saccharomyces cerevisiae threonine aldolase
Bacillus subtilis phosphopantetheinyl transferase
open reading frame
NW carried out all strain constructions, experiments, extractions, and drafted the manuscript. AH established the analysis methods and analyzed all samples. LL performed initial studies for the synthesis of (S)-2-ABA. NW and HH designed and coordinated the study. HH reviewed and edited the manuscript. All authors read and approved the final manuscript.
We would like to thank Prof. Nick Turner for helpful discussions on carboxylic acid reductases, and for suggestions on heterologous pathway prolongation, Dr. Bettina Nestl, Dr. Philipp Scheller, and Maike Lenz for supplying genes encoding imine reductases. We are grateful to Dr. Martina Geier and Prof. Anton Glieder for continuous support of the project. Finally, we thank Dr. Luke Simmons for proofreading the manuscript. This study was financed by the Innovative Medicines Initiative (IMI) Joint Undertaking project CHEM21 under Grant Agreement No 115360.
The authors declare that they have no competing interests.
Availability of data and materials
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
- El-Sayed ASA, Yassin MA, Ibrahim H. Coimmobilization of l-methioninase and glutamate dehydrogenase: novel approach for l-homoalanine synthesis. Biotechnol Appl Biochem. 2015;62:514–22.View ArticleGoogle Scholar
- Liao J, Zhang K, Cho K. Composition and methods for the production of l-homoalanine. Oakland, US; US patent 2016/0053236 A1.
- Leuchtenberger W, Huthmacher K, Drauz K. Biotechnological production of amino acids and derivatives: current status and prospects. Appl Microbiol Biotechnol. 2005;69:1–8.View ArticleGoogle Scholar
- Lloyd M, Bycroft M, Gade S. Preparation of (S)-2-aminobutyric acid. WO patent 2010/019469 A2.
- Yamaguchi S, Komeda H, Asano Y. New enzymatic method of chiral amino acid synthesis by dynamic kinetic resolution of amino acid amides: use of stereoselective amino acid amidases in the presence of α-amino-ε-caprolactam racemase. Appl Environ Microbiol. 2007;73:5370–3.View ArticleGoogle Scholar
- Park E, Kim M, Shin J-S. One-pot conversion of l-threonine into l-homoalanine: biocatalytic production of an unnatural amino acid from a natural one. Adv Synth Catal. 2010;352:3391–8.View ArticleGoogle Scholar
- Malik MS, Park E-S, Shin J-S. ω-Transaminase-catalyzed kinetic resolution of chiral amines using l-threonine as an amino acceptor precursor. Green Chem. 2012;14:2137–40.View ArticleGoogle Scholar
- Tao R, Jiang Y, Zhu F, Yang S. A one-pot system for production of L-2-aminobutyric acid from l-threonine by l-threonine deaminase and a NADH-regeneration system based on l-leucine dehydrogenase and formate dehydrogenase. Biotechnol Lett. 2014;36:835–41.View ArticleGoogle Scholar
- Han SW, Shin JS. Preparation of d-threonine by biocatalytic kinetic resolution. J Mol Catal B Enzym. 2015;122:227–32.View ArticleGoogle Scholar
- Seo Y-M, Mathew S, Bea H-S, Khang Y-H, Lee S-H, Kim B-G, et al. Deracemization of unnatural amino acid: homoalanine using d-amino acid oxidase and ω-transaminase. Org Biomol Chem. 2012;10:2482–5.View ArticleGoogle Scholar
- Zhu L, Tao R, Wang Y, Jiang Y, Lin X, Yang Y, et al. Removal of l-alanine from the production of l-2-aminobutyric acid by introduction of alanine racemase and d-amino acid oxidase. Appl Microbiol Biotechnol. 2011;90:903–10.View ArticleGoogle Scholar
- Dobrikov GM, Valcheva V, Stoilova-Disheva M, Momekov G, Tzvetkova P, Chimov A, et al. Synthesis and in vitro antimycobacterial activity of compounds derived from (R)- and (S)-2-amino-1-butanol—the crucial role of the configuration. Eur J Med Chem. 2012;48:45–56.View ArticleGoogle Scholar
- Häusler H, Kawakami RP, Mlaker E, Severn WB, Stütz AE. Ethambutol analogues as potential antimycobacterial agents. Bioorg Med Chem Lett. 2001;11:1679–81.View ArticleGoogle Scholar
- Citron K, Thomas G. Ocular toxicity from ethambutol. Thorax. 1986;41:737–9.View ArticleGoogle Scholar
- Periasamy M, Sivakumar S, Reddy M. New, convenient methods of synthesis and resolution of 1,2-amino alcohols. Synthesis. 2003;13:1965–7.View ArticleGoogle Scholar
- Singh B. Synthesis of ethambutol. US patent; 1976, US 3944618 A.
- Trost BM, Bunt RC, Lemoine RC, Calkins TL. Dynamic kinetic asymmetric transformation of diene monoepoxides: a practical asymmetric synthesis of vinylglycinol, vigabatrin, and ethambutol. J Am Chem Soc. 2000;122:5968–76.View ArticleGoogle Scholar
- Stauffer CS, Datta A. Efficient synthesis of (S, S)-ethambutol from l-methionine. Tetrahedron. 2002;58:9765–7.View ArticleGoogle Scholar
- Gonçalves RSB, Silva ET, De Souza MVN. An environmentally friendly, scalable and highly efficient synthesis of (S, S)-ethambutol, a first line drug against tuberculosis. Lett Org Chem. 2015;1:478–81.View ArticleGoogle Scholar
- Kotkar SP, Sudalai A. Enantioselective synthesis of (S, S)-ethambutol using proline-catalyzed asymmetric α-aminooxylation and α-amination. Tetrahedron Asymmetry. 2006;17:1738–42.View ArticleGoogle Scholar
- Kumar JK, Narsaiah AV. Stereoselective synthesis of tuberculostatic agent (S, S)-ethambutol. Org Commun. 2014;1:28–33.Google Scholar
- Paddon CJ, Keasling JD. Semi-synthetic artemisinin: a model for the use of synthetic biology in pharmaceutical development. Nat Rev Microbiol. 2014;12:355–67.View ArticleGoogle Scholar
- Patel RN. Synthesis of chiral pharmaceutical intermediates by biocatalysis. Coord Chem Rev. 2008;252:659–701.View ArticleGoogle Scholar
- Pollard DJ, Woodley JM. Biocatalysis for pharmaceutical intermediates: the future is now. Trends Biotechnol. 2007;25:66–73.View ArticleGoogle Scholar
- Szczebara FM, Chandelier C, Villeret C, Masurel A, Bourot S, Duport C, et al. Total biosynthesis of hydrocortisone from a simple carbon source in yeast. Nat Biotechnol. 2003;21:143–9.View ArticleGoogle Scholar
- Zhang K, Li H, Cho KM, Liao JC. Expanding metabolism for total biosynthesis of the nonnatural amino acid l-homoalanine. Proc Natl Acad Sci USA. 2010;107:6234–9.View ArticleGoogle Scholar
- Nguyen LT, Nguyen KT, Spfek J. The tylosin producer, Streptomyces fradiae, contains a second valine dehydrogenase. Microbiology. 1995;141:1139–45.View ArticleGoogle Scholar
- Hansen EH, Møller BL, Kock GR, Bünner CM, Kristensen C, Jensen OR, et al. De novo biosynthesis of vanillin in fission yeast (Schizosaccharomyces pombe) and baker’s yeast (Saccharomyces cerevisiae). Appl Environ Microbiol. 2009;75:2765–74.View ArticleGoogle Scholar
- Kanehisa M, Sato Y, Kawashima M, Furumichi M, Tanabe M. KEGG as a reference resource for gene and protein annotation. Nucleic Acids Res. 2016;44:D457–62.View ArticleGoogle Scholar
- Ramos C, Delgado MA, Calderon IL. Inhibition by different amino acids of the aspartate kinase and the homoserine kinase of the yeast Saccharomyces cerevisiae. FEBS Lett. 1991;278:123–6.View ArticleGoogle Scholar
- Ramos C, Calderon IL. Overproduction of threonine by Saccharomyces cerevisiae mutants resistant to hydroxynorvaline. Appl Environ Microbiol. 1992;58:1677–82.Google Scholar
- Martin-Rendon E, Farfan M, Ramos C, Calderon I. Isolation of a mutant allele that deregulates the threonine biosynthesis in Saccharomyces cerevisiae. Curr Genet. 1993;24:465–71.View ArticleGoogle Scholar
- Otero JM, Cimini D, Patil KR, Poulsen SG, Olsson L, Nielsen J. Industrial systems biology of Saccharomyces cerevisiae enables novel succinic acid cell factory. PLoS ONE. 2013;8:e54144.View ArticleGoogle Scholar
- McNeil JB, McIntosh EM, Taylor BV, Zhang FR, Tang S, Bognar A. Cloning and molecular characterization of three genes, including two genes encoding serine hydroxymethyltransferases, whose inactivation is required to render yeast auxotrophic for glycine. J Biol Chem. 1994;269:9155–65.Google Scholar
- Monschau N, Stahmann KP, Sahm H, McNeil JB, Bognar AL. Identification of Saccharomyces cerevisiae GLY1 as a threonine aldolase: a key enzyme in glycine biosynthesis. FEMS Microbiol Lett. 1997;150:55–60.View ArticleGoogle Scholar
- Szamosi I, Shaner DL, Singh BK. Identification and characterization of a biodegradative form of threonine dehydratase in senescing tomato (Lycopersicon esculentum) leaf. Plant Physiol. 1993;101:999–1004.View ArticleGoogle Scholar
- Shizuta Y, Hayaishi O. Regulation of biodegradative threonine deaminase. Curr Top Cell Regul. 1976;11:99–146.View ArticleGoogle Scholar
- Shulman A, Zalyapin E, Vyazmensky M, Yifrach O, Barak Z, Chipman DM. Allosteric regulation of Bacillus subtilis threonine deaminase, a biosynthetic threonine deaminase with a single regulatory domain. Biochemistry. 2008;47:11783–92.View ArticleGoogle Scholar
- Reed MC, Lieb A, Nijhout HF. The biological significance of substrate inhibition: a mechanism with diverse functions. BioEssays. 2010;32:422–9.View ArticleGoogle Scholar
- Iraqui I, Vissers S, Bernard F, De Craene JO, Boles E, Urrestarazu A, et al. Amino acid signaling in Saccharomyces cerevisiae: a permease-like sensor of external amino acids and F-box protein Grr1p are required for transcriptional induction of the AGP1 gene, which encodes a broad-specificity amino acid permease. Mol Cell Biol. 1999;19:989–1001.View ArticleGoogle Scholar
- Regenberg B, Düring-Olsen L, Kielland-Brandt MC, Holmberg S. Substrate specificity and gene expression of the amino-acid permeases in Saccharomyces cerevisiae. Curr Genet. 1999;36:317–28.View ArticleGoogle Scholar
- Velasco I, Tenreiro S, Calderon IL, Andre B. Saccharomyces cerevisiae Aqr1 is an internal-membrane transporter involved in excretion of amino acids. Eukaryot Cell. 2004;3:1492–503.View ArticleGoogle Scholar
- Mülleder M, Calvani E, Alam MT, Wang RK, Eckerstorfer F, Zelezniak A, Ralser M. Functional metabolomics describes the yeast biosynthetic regulome. Cell. 2016;167:553–65.View ArticleGoogle Scholar
- Alarcon CM, Heitman J. FKBP12 physically and functionally interacts with aspartokinase in Saccharomyces cerevisiae. Mol Cell Biol. 1997;17:5968–75.View ArticleGoogle Scholar
- Valli M, Sauer M, Branduardi P, Borth ND. Intracellular pH distribution in Saccharomyces cerevisiae cell populations, analyzed by flow cytometry. Appl Environ Microbiol. 2005;71:1515–21.View ArticleGoogle Scholar
- Akhtar MK, Turner NJ, Jones PR. Carboxylic acid reductase is a versatile enzyme for the conversion of fatty acids into fuels and chemical commodities. Proc Natl Acad Sci USA. 2013;110:87–92.View ArticleGoogle Scholar
- Zhou YJ, Buijs NA, Zhu Z, Qin J, Siewers V, Nielsen J. Production of fatty acid-derived oleochemicals and biofuels by synthetic yeast cell factories. Nat Commun. 2016;7:11709.View ArticleGoogle Scholar
- Moura M, Pertusi D, Lenzini S, Bhan N, Broadbelt LJ, Tyo KEJJ. Characterizing and predicting carboxylic acid reductase activity for diversifying bioaldehyde production. Biotechnol Bioeng. 2016;113:944–52.View ArticleGoogle Scholar
- Kara S, Schrittwieser JH, Hollmann F, Ansorge-Schumacher MB. Recent trends and novel concepts in cofactor-dependent biotransformations. Appl Microbiol Biotechnol. 2014;98:1517–29.View ArticleGoogle Scholar
- Weber N, Gorwa-Grauslund M, Carlquist M. Improvement of whole-cell transamination with Saccharomyces cerevisiae using metabolic engineering and cell pre-adaptation. Microb Cell Fact. 2017;16:3.View ArticleGoogle Scholar
- Weber N, Gorwa-Grauslund M, Carlquist M. Exploiting cell metabolism for biocatalytic whole-cell transamination by recombinant Saccharomyces cerevisiae. Appl Microbiol Biotechnol. 2014;98:4615–24.View ArticleGoogle Scholar
- Verho R, Londesborough J, Penttilä M, Richard P. Engineering redox cofactor regeneration for improved pentose fermentation in Saccharomyces cerevisiae. Appl Environ Microbiol. 2003;69:5892–7.View ArticleGoogle Scholar
- Perez-Zabaleta M, Sjöberg G, Guevara-Martínez M, Jarmander J, Gustavsson M, Quillaguamán J, et al. Increasing the production of (R)-3-hydroxybutyrate in recombinant Escherichia coli by improved cofactor supply. Microb Cell Fact. 2016;15:91.View ArticleGoogle Scholar
- Dos Santos MM, Raghevendran V, Kötter P, Olsson L, Nielsen J. Manipulation of malic enzyme in Saccharomyces cerevisiae for increasing NADPH production capacity aerobically in different cellular compartments. Metab Eng. 2004;6:352–63.View ArticleGoogle Scholar
- Nevoigt E. Progress in metabolic engineering of Saccharomyces cerevisiae. Microbiol Mol Biol Rev. 2008;72:379–412.View ArticleGoogle Scholar
- Zhao X, Shi F, Zhan W. Overexpression of ZWF1 and POS5 improves carotenoid biosynthesis in recombinant Saccharomyces cerevisiae. Lett Appl Microbiol. 2015;61:354–60.View ArticleGoogle Scholar
- Joska T, Mashruwala A, Boyd J, Belden W. A universal cloning method based on yeast homologous recombination that is simple, efficient, and versatile. J Microbiol Methods. 2014;100:46–51.View ArticleGoogle Scholar
- van Leeuwen J, Andrews B, Boone C, Tan G. Rapid and efficient plasmid construction by homologous recombination in yeast. Cold Spring Harb Protoc. 2015 (9).
- Eichenberger M, Lehka B, Folly C, Fischer D, Martens E, Naesby M. Metabolic engineering of Saccharomyces cerevisiae for de novo production of dihydrochalcones with known antioxidant, antidiabetic, and sweet tasting properties. Metab Eng. 2017;39:80–9.View ArticleGoogle Scholar
- Gietz RD, Schiestl RH. High-efficiency yeast transformation using the LiAc/SS carrier DNA/PEG method. Nat Protoc. 2008;2:31–5.View ArticleGoogle Scholar
- Samach A, Hareven D, Gutfinger T, Lifschitz E. Biosynthetic threonine deaminase gene of tomato: isolation, structure, and upregulation in floral organs. Dev Biol. 1991;88:2678–82.Google Scholar